Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | IDH2 wild-type |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
IDH2 wild-type | high grade glioma | not applicable | N/A | Guideline | Risk Factor | IDH2 wild-type is associated with increased risk of aggressive disease in patients with grade II or III infiltrative gliomas (NCCN.org). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03018288 | Phase II | Pembrolizumab + Temozolomide Pembrolizumab + Temozolomide + Vitespen | Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) | Active, not recruiting | USA | 0 |
NCT03631836 | Phase I | Andecaliximab + Bevacizumab | Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma (MARELLE01) | Unknown status | FRA | 0 |
NCT04225039 | Phase II | INCAGN01876 + Retifanlimab | Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma | Active, not recruiting | USA | 0 |
NCT03696355 | Phase I | GDC-0084 | Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas | Active, not recruiting | USA | 0 |
NCT03452930 | Phase I | Tinostamustine | Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma | Active, not recruiting | USA | 0 |